

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Samuel R. Denmeade, *et al.*  
Serial No.: 10/535,351  
Filed: April 14, 2006  
Title: ACTIVATION OF PEPTIDE PRODRUGS BY HK2  
Confirmation No: 7060  
Art Unit: 1654  
Examiner: Maury A. Audet

MAIL STOP: AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER SUBMISSION**

Dear Sir:

In response to a pending provisional double patenting rejection over co-pending application 11/725,135, Applicants submit a terminal disclaimer executed by the Assignee of the present application. Applicants also submit Assignee statements under 37 CFR 3.73(b) showing common ownership of the present application and co-pending application 11/725,135.

Applicants submit the required statutory disclaimer fee in the small entity amount of \$70 set forth in 37 CFR 1.20(d). If any other fees are due and are not included, the Director is authorized to charge any fees or credit any overpayment due to Deposit Account No. 23-2426 of Winstead PC (referencing matter 50562-P001US).


If there are any questions concerning this paper or the present application in general, the undersigned may be contacted at 713-650-2663.

Respectfully submitted,

WINSTEAD PC

Agent for Applicants

Date: May 19, 2010

By:   
Thomas P. Thrash, Reg. No. 64,805

Mail correspondence to :

WINSTEAD P.C.  
P. O. Box 50784  
Dallas, Texas 75201  
Tel: 713.650.2764  
Fax: 214.745.5390